CUL4A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15570369	1.00	7/20
SCHEMBL15571207	1.00	7/20
SCHEMBL15572039	1.00	7/20
SCHEMBL15572548	1.00	7/20
SCHEMBL15571179	1.00	6/20
SCHEMBL15571642	1.00	6/20
SCHEMBL15571850	1.00	6/20
SCHEMBL15572132	1.00	6/20
SCHEMBL15572315	1.00	6/20
SCHEMBL1539839	0.73	6/20
SCHEMBL15572213	0.68	6/20
SCHEMBL834711	0.61	6/20
SCHEMBL9920159	0.56	6/20
SCHEMBL15571970	0.53	6/20
SCHEMBL15570742	0.50	6/20
SCHEMBL1539855	0.45	6/20
SCHEMBL15570426	1.00	5/20
SCHEMBL15571112	1.00	5/20
SCHEMBL15571481	1.00	5/20
SCHEMBL15571494	1.00	5/20

Clinical trials — most relevant to CUL4A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Olaparib in Patients With HRD Malignant Mesothelioma	PHASE2	RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
ADAPT: Efficacy of a Dietary Supplement During and After Exercise	nan	COMPLETED
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Characterization of Angelman Syndrome	nan	COMPLETED
Angelman Syndrome Natural History Study	nan	RECRUITING
Ohio Colorectal Cancer Prevention Initiative	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Italian Angelman Syndrome Registry	nan	COMPLETED
Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Better Delineation of DDX3X Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.	nan	COMPLETED
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders	nan	RECRUITING
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study	nan	RECRUITING
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
Drivers of Hypoxia-induced Angiogenesis in Tumor Development	nan	UNKNOWN
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CUL4A binder may also engage these)

Protein	Name	Similarity
Q3TCH7	—	1.000	Q3TCH7 →
CUL4B	Cullin-4B	0.980	landscape →
A2A432	—	0.967	A2A432 →
Q99LD4	—	0.944	Q99LD4 →
P97834	—	0.942	P97834 →
P17427	—	0.942	P17427 →
P18484	—	0.942	P18484 →
GPS1	COP9 signalosome complex subunit 1	0.942	landscape →
Q80U96	—	0.941	Q80U96 →
Q6NRT5	—	0.940	Q6NRT5 →
Q5NVP9	—	0.940	Q5NVP9 →
Q6AYU1	—	0.940	Q6AYU1 →
XPO1	Exportin-1	0.940	landscape →
Q6P5F9	—	0.938	Q6P5F9 →
AP2A2	AP-2 complex subunit alpha-2	0.938	landscape →
DHX9	ATP-dependent RNA helicase A	0.938	landscape →
Q5R874	—	0.937	Q5R874 →
Q5XHZ9	—	0.935	Q5XHZ9 →
Q5XIT1	—	0.934	Q5XIT1 →
E2R222	—	0.934	E2R222 →
Q7SXR3	—	0.934	Q7SXR3 →
COPS2	COP9 signalosome complex subunit 2	0.934	landscape →
Q6PER3	—	0.933	Q6PER3 →
Q6PFJ9	—	0.933	Q6PFJ9 →
Q0VCK5	—	0.933	Q0VCK5 →
TRIP13	Pachytene checkpoint protein 2 homolog	0.932	landscape →
DCUN1D2	DCN1-like protein 2	0.932	landscape →
Q28141	—	0.932	Q28141 →
Q8BG32	—	0.932	Q8BG32 →
Q6GR10	—	0.932	Q6GR10 →